Synonym
Egyt 2509; Egyt2509; Egyt-2509;
IUPAC/Chemical Name
3-(2-chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-N,N,2-trimethylpropan-1-amine hydrochloride
InChi Key
FZCRQGMMAHHLMV-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H23ClN2O2.ClH/c1-14(11-21(2)3)12-22-16-6-4-5-7-18(16)23-13-24-19-9-8-15(20)10-17(19)22;/h4-10,14H,11-13H2,1-3H3;1H
SMILES Code
CC(CN1c2c(OCOc3c1cc(Cl)cc3)cccc2)CN(C)C.Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
383.31
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: István G, Gyertyán I, Gigler G, Somogyi E, Petöcz L. Possible involvement of the antiserotoninergic and antihistaminergic activity in the anticataleptogenic effect of EGYT-2509. Acta Physiol Hung. 1990;75 Suppl:119-20. PMID: 1973556.
2: Dóda M. Interactions of apomorphine and a novel neuroleptic dibenzodioxazocine derivative, as evidenced by changes of somato-autonomic reflexes and spontaneous sympathetic activity in cats. J Pharm Pharmacol. 1989 Aug;41(8):549-54. doi: 10.1111/j.2042-7158.1989.tb06524.x. PMID: 2571699.
3: Gaál J, Batke J, Borsodi A, Rózsa L, Somogyi G. Synthesis of dibenzodioxazocines and their effects on cholinesterases and muscarinic cholinergic receptors. Acta Biochim Biophys Hung. 1989;24(1-2):129-42. PMID: 2514534.
4: Gacsályi I, Petöcz L, Fekete MI, Bükkfálvi B, Görgenyi F, Arató M. EGYT-2509 a novel neuroleptic agent without extrapyramidal and endocrine side effects. Pol J Pharmacol Pharm. 1988 Nov-Dec;40(6):613-9. PMID: 2908364.
5: Kövér G, Fekete M, Tost H, Szemerédi K. The combined effects of dopamine (DA) and the DA antagonists EGYT-2509, chlorpromazine and haloperidol on the kidney function. Acta Physiol Hung. 1988;72(3-4):321-33. PMID: 3250211.
6: Gyüre K, Szentendrei T, Kanyicska B, Fekete MI, Rónai AZ. Dopamine receptor binding of a novel dibenzodioxazocine derivative, EGYT-2509. Pol J Pharmacol Pharm. 1985 May-Jun;37(3):253-61. PMID: 2866498.
